Adding Tafasitamab to Lenalidomide and Rituximab Prolongs PFS in Patients with Relapsed or Refractory Follicular Lymphoma By Ogkologos - December 18, 2025 116 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the inMIND study Source RELATED ARTICLESMORE FROM AUTHOR Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe Updated Oncogene-Addicted mNSCLC Living Guideline v1.3 FDA Approves Pembrolizumab with Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma MOST POPULAR What to Know About 3 Common Misconceptions Around Food and Cancer... April 25, 2023 ΚΑΡΚΙΝΟΣ ΤΡΑΧΗΛΟΥ ΜΗΤΡΑΣ December 16, 2018 Extended Lymphadenectomy Does Not Improve DFS or OS Among Patients with... November 4, 2024 A Lack of Resistance Gene Alterations in Baseline ctDNA Associated with... February 16, 2024 Load more HOT NEWS Bjorn Saven: “By supporting early career researchers to do their jobs... What Comes after NCI-MATCH? NCI’s New Precision Medicine Cancer Trials When Ovarian Cancer Returns, Surgery May Be a Good Choice for... Adjuvant Nivolumab Prolongs DFS in Patients with Resected Osophageal or Gastroesophageal...
